Zippin Bio has been awarded a $700K NIH Phase I SBIR grant to advance the delivery platform designed to cross the blood–brain barrier (BBB) - a critical step toward enabling safer and more effective treatments for neurological diseases.

This award supports continued platform development and early validation of company's approach, positioning the technology for future translational impact. We thank NINDS for recognizing the promise of this work, and we’re deeply grateful to our team and mentors whose scientific rigor and sustained commitment continue to drive progress.